Literature DB >> 23648436

Utilization of surgery, chemotherapy, radiation therapy, and hospice at the end of life for patients diagnosed with metastatic melanoma.

Jinhai Huo1, Xianglin L Du, David R Lairson, Wenyaw Chan, Jing Jiang, Thomas A Buchholz, B Ashleigh Guadagnolo.   

Abstract

OBJECTIVES: To examine the patterns of utilization of radiation therapy, chemotherapy, surgery, and hospice at the end-of-life care for patients diagnosed with metastatic melanoma.
METHODS: We identified 816 Medicare beneficiaries toward who were 65 years of age or older, with pathologically confirmed metastatic malignant melanoma between January 1, 2000, and December 31, 2007. We evaluated trends and associations between sociodemographic and health service characteristics and the use of hospice care, chemotherapy, surgery, and radiation therapy.
RESULTS: We found increasing use of surgery for patients with metastatic melanoma from 13% in 2000 to 30% in 2007 (P=0.03 for trend), and no significant fluctuation in the use of chemotherapy (P=0.43) or radiation therapy (P=0.46). Older patients were less likely to receive radiation therapy or chemotherapy. The use of hospice care increased from 61% in 2000 to 79% in 2007 (P=0.07 for trend). Enrollment in short-term (1 to 3 d) hospice care use increased, whereas long-term hospice care (≥4 d) remained stable. Patients living in the SEER (Surveillance, Epidemiology and End Results) northeast and south regions were less likely to undergo surgery. Patients enrolled in long-term hospice care used significantly less chemotherapy, surgery, and radiation therapy.
CONCLUSIONS: Surgery and hospice care use increased over the years of this study, whereas the use of chemotherapy and radiation therapy remained consistent for patients diagnosed with metastatic melanoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 23648436      PMCID: PMC3796177          DOI: 10.1097/COC.0b013e31829378f9

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  22 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  Melanoma incidence and mortality among US whites, 1969-1999.

Authors:  Alan C Geller; Donald R Miller; George David Annas; Marie-France Demierre; Barbara A Gilchrest; Howard K Koh
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

3.  Hospice use before death: variability across cancer diagnoses.

Authors:  Beth A Virnig; A Marshall McBean; Sara Kind; Rishi Dholakia
Journal:  Med Care       Date:  2002-01       Impact factor: 2.983

4.  Geographic variation in hospice use prior to death.

Authors:  B A Virnig; S Kind; M McBean; E Fisher
Journal:  J Am Geriatr Soc       Date:  2000-09       Impact factor: 5.562

5.  Hospice use among Medicare managed care and fee-for-service patients dying with cancer.

Authors:  Ellen P McCarthy; Risa B Burns; Quyen Ngo-Metzger; Roger B Davis; Russell S Phillips
Journal:  JAMA       Date:  2003-05-07       Impact factor: 56.272

6.  Decreasing variation in the use of hospice among older adults with breast, colorectal, lung, and prostate cancer.

Authors:  Nuha A Lackan; Glenn V Ostir; Jean L Freeman; Jonathan D Mahnken; James S Goodwin
Journal:  Med Care       Date:  2004-02       Impact factor: 2.983

7.  Trends in the aggressiveness of cancer care near the end of life.

Authors:  Craig C Earle; Bridget A Neville; Mary Beth Landrum; John Z Ayanian; Susan D Block; Jane C Weeks
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

8.  Chemotherapy use among Medicare beneficiaries at the end of life.

Authors:  Ezekiel J Emanuel; Yinong Young-Xu; Norman G Levinsky; Gail Gazelle; Olga Saynina; Arlene S Ash
Journal:  Ann Intern Med       Date:  2003-04-15       Impact factor: 25.391

9.  Place of death and its predictors for local patients registered at a comprehensive cancer center.

Authors:  Eduardo Bruera; Nancy Russell; Catherine Sweeney; Michael Fisch; J Lynn Palmer
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

10.  Family perspectives on end-of-life care at the last place of care.

Authors:  Joan M Teno; Brian R Clarridge; Virginia Casey; Lisa C Welch; Terrie Wetle; Renee Shield; Vincent Mor
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

View more
  6 in total

1.  Hospice Utilization in Elderly Patients With Brain Metastases.

Authors:  Elie K Mehanna; Paul J Catalano; Daniel N Cagney; Daphne A Haas-Kogan; Brian M Alexander; James A Tulsky; Ayal A Aizer
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

2.  Trends in end-of-life care and health care spending in women with uterine cancer.

Authors:  Benjamin Margolis; Ling Chen; Melissa K Accordino; Grace Clarke Hillyer; June Y Hou; Ana I Tergas; William M Burke; Alfred I Neugut; Cande V Ananth; Dawn L Hershman; Jason D Wright
Journal:  Am J Obstet Gynecol       Date:  2017-07-11       Impact factor: 8.661

3.  Long-term outcomes of helper peptide vaccination for metastatic melanoma.

Authors:  Yinin Hu; Helen Kim; Christopher M Blackwell; Craig L Slingluff
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

4.  Trends and racial disparities in aggressive end-of-life care for a national sample of women with ovarian cancer.

Authors:  Megan A Mullins; Julie J Ruterbusch; Philippa Clarke; Shitanshu Uppal; Lauren P Wallner; Michele L Cote
Journal:  Cancer       Date:  2021-02-25       Impact factor: 6.921

5.  Developing Predictive Models to Determine Patients in End-of-Life Care in Administrative Datasets.

Authors:  Joel N Swerdel; Jenna M Reps; Daniel Fife; Patrick B Ryan
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

6.  Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.

Authors:  Annemarie C Eggen; Geke A P Hospers; Ingeborg Bosma; Miranda C A Kramer; Anna K L Reyners; Mathilde Jalving
Journal:  BMC Cancer       Date:  2022-03-05       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.